SEC Info - CollPlant Biotechnologies Ltd.

SEC Info℠

Home

Help

Please Sign In

CollPlant Biotechnologies Ltd. – ‘6-K’ for 1/2/24

On: Tuesday, 1/2/24, at 7:09am ET · For: 1/2/24 · Accession #: 1213900-24-38 · File #: 1-38370

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/02/24  CollPlant Biotechnologies Ltd.    6-K         1/02/24    2:44K                                    EdgarAgents LLC/FA

Current, Quarterly or Annual Report by a Foreign Issuer — Form 6-K — SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Report of Foreign Private Issuer                    HTML     11K 
 2: EX-99.1     Press Release, Dated January 2, 2024                HTML     15K

‘6-K’ — Report of Foreign Private Issuer

This is an HTML Document rendered as filed. [ Alternative Formats ]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2024

Commission File Number 001-38370

CollPlant Biotechnologies Ltd.

(Exact name of registrant as specified in its charter)

4 Oppenheimer St, Weizmann Science Park

Rehovot 7670104, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

This first paragraph of the press release attached to this Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-229163, 333-248479, 333-263842 and 333-271320) and Form F-3 (File No. 333-228054, 333-238731 and 333-269087), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

On January 2, 2024, CollPlant Biotechnologies Ltd. issued a press release entitled “CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants”. A copy of the letter is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit
99.1		Press Release, dated January 2, 2024

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	COLLPLANT BIOTECHNOLOGIES LTD.

Date: January 2, 2024	By:	/s/ *Eran Rotem*
		Name:	Eran Rotem
		Title:	Deputy CEO and Chief Financial Officer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘6-K’ Filing	Date	Other Filings

Filed on / For Period end:	1/2/24	None on these Dates
		List all Filings

7 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/18/23  CollPlant Biotechnologies Ltd.    S-8         4/18/23    4:201K                                   EdgarAgents LLC/FA
12/30/22  CollPlant Biotechnologies Ltd.    F-3                    6:415K                                   EdgarAgents LLC/FA
 3/25/22  CollPlant Biotechnologies Ltd.    S-8         3/25/22    4:81K                                    EdgarAgents LLC/FA
 8/28/20  CollPlant Biotechnologies Ltd.    S-8         8/28/20    3:116K                                   EdgarAgents LLC/FA
 5/27/20  CollPlant Biotechnologies Ltd.    F-3                    3:479K                                   EdgarAgents LLC/FA
 4/08/19  CollPlant Biotechnologies Ltd.    F-3/A                  3:425K                                   EdgarAgents LLC/FA
 1/08/19  CollPlant Biotechnologies Ltd.    S-8         1/08/19    3:101K                                   EdgarAgents LLC/FA

↑Top

Filing Submission 0001213900-24-000038 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)